다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Peregrine Pharmaceuticals Inc. (MM) (PPHMD)
Peregrine Pharmaceuticals Inc. (MM) (PPHMD) 뉴스

PPHMD

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Peregrine Pharmaceuticals Inc. (MM)

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:PPHMD

1

일자	시간	출처	헤드라인	심볼	기업
2019/03/30	07:42	Business Wire	Announcing VanEck Vectors ETFs’ March 2019 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2018/12/27	08:37	Business Wire	Announcing VanEck Vectors Equity ETFs December 2018 Distribution	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2018/10/18	00:48	Business Wire	VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2018/09/29	07:03	Business Wire	Announcing VanEck Vectors Equity ETFs’ September 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2018/06/30	07:15	Business Wire	Announcing VanEck Vectors Equity ETFs June 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2018/03/30	06:58	Business Wire	Announcing VanEck Vectors Equity ETFs March 2018 Distributions	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2009/11/10	23:30	PR Newswire (US)	New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Canc	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2009/11/05	04:17	PR Newswire (US)	Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2009/11/04	05:00	PR Newswire (US)	Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements	NASDAQ:PPHMD
2009/10/27	21:17	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2009/10/24	06:34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)
2009/10/21	22:30	PR Newswire (US)	Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer	NASDAQ:PPHMD
2009/10/19	22:30	PR Newswire (US)	Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs	NASDAQ:PPHMD
2009/10/19	21:30	PR Newswire (US)	Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes Effect	NASDAQ:PPHMD
2009/10/19	20:44	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:PPHMD	Peregrine Pharmaceuticals Inc. (MM)

검색 관련기사 보기:NASDAQ:PPHMD

1

Satus 21-1.28 D

SER EDUCACIONAL ON

Banco Santander Totta 0....

Yamashin Filter (PK)

NLBNPIT1XFR6 20351221 11...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관